US EditionPublished • loading... • Updated
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
The Phase 3 trial will enroll 600 Chinese gout patients to compare tigulixostat's efficacy and safety against febuxostat, addressing rising gout prevalence and treatment gaps in China.
Summary by Helena Independent Record
4 Articles
4 Articles
Helena Independent Record+3 Reposted by 3 other sources
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…
·Helena, United States
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left0Leaning Right0Center3Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
